`
`
`
`
`
`
`UNITED STATES DISTRICT COURT
`DISTRICT OF DELAWARE
`
`
`FRESENIUS KABI USA, LLC,
`
`
`
`
`
`v.
`
`Plaintiff,
`
`DR. REDDY’S LABORATORIES, LTD. and DR.
`REDDY’S LABORATORIES, INC.,
`
`Defendants.
`
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`
`Civil Action No. ________
`
`COMPLAINT
`
`Fresenius Kabi USA, LLC (“Fresenius”) brings this action for patent infringement
`
`against Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc. (collectively and/or
`
`individually “DRL”).
`
`
`
`1.
`
`This is an action by Fresenius against Defendants for infringement of United
`
`States Patent No. 8,476,010 (“the ʼ010 patent”). This action arises out of DRL’s filing of an
`
`Abbreviated New Drug Application (“ANDA”) seeking approval by the United States Food and
`
`Drug Administration (“FDA”) to sell generic versions of Diprivan®, an innovative intravenously
`
`administered sedative and anesthetic, prior to the expiration of the ʼ010 patent.
`
`
`
`
`
`
`
`Case 1:14-cv-00160-RGA Document 1 Filed 02/06/14 Page 2 of 9 PageID #: 2
`
`
`
`Fresenius
`
`THE PARTIES
`
`2.
`
`Fresenius is a Delaware limited liability company with its principal place of
`
`business at Three Corporate Drive, Lake Zurich, Illinois 60047. Fresenius Kabi USA, LLC was
`
`formerly known as APP Pharmaceuticals, LLC (“APP”).
`
`DRL
`
`3.
`
`Upon information and belief, Defendant Dr. Reddy’s Laboratories, Ltd. (“DRL
`
`Ltd.”) is a corporation operating and existing under the laws of India, with its principal place of
`
`business at 8-2-337, Road No. 3, Banjara Hills, Hyderabad, 500034, India.
`
`4.
`
`Upon information and belief, Defendant Dr. Reddy’s Laboratories, Inc. (“DRL
`
`Inc.”) is a New Jersey corporation with its principal place of business at 200 Somerset Corporate
`
`Boulevard, Building II, 7th Floor, Bridgewater, NJ 08807.
`
`5.
`
`On information and belief, Defendant Dr. Reddy’s Inc. is a wholly-owned
`
`subsidiary of Dr. Reddy’s Ltd., and is controlled by Dr. Reddy’s Ltd.
`
`6.
`
`On information and belief, both DRL Inc. and DRL Ltd. submitted, collaborated
`
`and/or acted in concert in the preparation or submission of ANDA Number 205067 (“DRL
`
`ANDA”).
`
`Subject Matter Jurisdiction
`
`JURISDICTION AND VENUE
`
`7.
`
`8.
`
`This action for patent infringement arises under 35 U.S.C. § 271.
`
`This Court has jurisdiction over the subject matter of this action pursuant to 28
`
`U.S.C. §§ 1331, 1338(a), 2201 and 2202.
`
`
`
`2
`
`
`
`Case 1:14-cv-00160-RGA Document 1 Filed 02/06/14 Page 3 of 9 PageID #: 3
`
`
`
`Personal Jurisdiction Over DRL
`
`9.
`
`Upon information and belief, this Court has personal jurisdiction over DRL, at
`
`least because DRL has engaged in continuous and systematic contacts with Delaware and/or
`
`purposefully availed itself of this forum by, among other things, making, shipping, using,
`
`offering to sell or selling, or causing others to use, offer to sell, or sell, DRL’s pharmaceutical
`
`products in this Judicial District, and deriving substantial revenue from such activities.
`
`10.
`
`Further, DRL has previously admitted in Merck & Co., Inc. v. Dr. Reddy’s Labs,
`
`Ltd., Mo. 04-1313 (GMS) that due to their many contacts with Delaware they were “subject to
`
`personal jurisdiction in this judicial district.”
`
`Venue
`
`11.
`
`Venue is proper in this Judicial District under 28 U.S.C. § 1391 and 1400(b).
`
`The Patent-in-Suit: United States Patent No. 8,476,010
`
`BACKGROUND
`
`12.
`
`The ʼ010 patent, entitled “Propofol Formulations with Non-Reactive Container
`
`Closures,” was duly and lawfully issued on July 2, 2013 to inventors Neil P. Desai, Andrew
`
`Yang, and Sherry Xiaopei Ci. The named inventors assigned the ʼ010 patent to APP
`
`Pharmaceuticals, LLC, which later changed its name to Fresenius Kabi USA, LLC.
`
`Accordingly, Fresenius is the owner of all rights, title, and interest in the ʼ010 patent. The ʼ010
`
`patent is listed in the FDA publication “Approved Drug Products with Therapeutic Equivalence
`
`Evaluations,” commonly referred to as “The Orange Book” (“Orange Book”) with respect to
`
`Diprivan®. The ʼ010 patent will expire on June 1, 2025. A true and accurate copy of the ʼ010
`
`patent is attached hereto as Exhibit A.
`
`
`
`
`
`3
`
`
`
`Case 1:14-cv-00160-RGA Document 1 Filed 02/06/14 Page 4 of 9 PageID #: 4
`
`
`
`The Diprivan® Drug Product
`
`13.
`
`Fresenius currently sells, promotes, distributes, and markets Diprivan® (propofol)
`
`injectable emulsion in the United States.
`
`14.
`
`Diprivan® is indicated, generally speaking, for the induction and maintenance of
`
`general anesthesia and sedation in certain patient populations.
`
`15.
`
`Fresenius holds an approved New Drug Application (“NDA”) No. 19627 under
`
`Section 505(b) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 355(a) in connection
`
`with the Diprivan® 1% (propofol) injectable emulsion product containing 10 mg propofol per 1
`
`ml of emulsion.
`
`The DRL ANDA
`
`16.
`
`DRL filed with the FDA an ANDA under 21 U.S.C. § 355(j) seeking approval to
`
`manufacture, use, offer for sale, sell in and import into the United States a propofol injectable
`
`emulsion containing 10mg propofol per 1 ml of emulsion that DRL asserts is a generic copy of
`
`Diprivan® (“DRL’s generic Diprivan® product”) prior to the expiration of the ʼ010 patent.
`
`17.
`
`18.
`
`The FDA assigned the DRL ANDA number 205067.
`
`By letter dated April 11, 2013, DRL notified Fresenius that it had filed an ANDA
`
`seeking approval to market DRL’s generic Diprivan® product prior to the patents then listed in
`
`the Orange Book (“DRL Notice Letter”).
`
`19.
`
`The ʼ010 patent had not issued at the time DRL submitted its certification under
`
`§ 505(j)(2)(A)(vii)(IV) of the Federal Food, Drug and Cosmetic Act.
`
`20.
`
`DRL is required to amend the patent certification in its ANDA to address the ʼ010
`
`patent prior to approval of its ANDA but, on information and belief, has yet to do so. Despite
`
`
`
`4
`
`
`
`Case 1:14-cv-00160-RGA Document 1 Filed 02/06/14 Page 5 of 9 PageID #: 5
`
`
`
`repeated requests by Plaintiff's counsel, DRL has, to date, refused to disclose whether it will
`
`submit a Paragraph IV certification as to the ʼ010 patent.
`
`COUNT I FOR INFRINGEMENT OF U.S. PATENT NO. 8,476,010 BY DRL
`
`21.
`
`The allegations of paragraphs 1-20 are realleged and incorporated herein by
`
`reference.
`
`22.
`
`The use of DRL’s generic Diprivan® product is covered by one or more claims of
`
`the ʼ010 patent.
`
`23.
`
`The commercial manufacture, use, offer for sale, sale, marketing, distribution,
`
`and/or importation of DRL’s generic Diprivan® product would infringe one or more claims of the
`
`ʼ010 patent.
`
`24.
`
`DRL has infringed the ʼ010 patent by submitting the DRL ANDA to the FDA
`
`seeking approval to market DRL’s generic Diprivan® product containing propofol before the
`
`expiration of the ʼ010 patent.
`
`25.
`
`Upon information and belief, Defendants DRL Inc. and DRL Ltd. acted in concert
`
`and actively and knowingly caused to be submitted, assisted with, participated in, encouraged,
`
`contributed to, aided and abetted, and/or directed the submission of the DRL ANDA to the FDA.
`
`26.
`
`Defendants DRL Inc. and DRL Ltd. induced the infringement of the ʼ010 patent
`
`by actively and knowingly aiding and abetting the preparation and submission of the DRL
`
`ANDA and in the preparation to sell DRL’s generic Diprivan® product in the United States.
`
`27.
`
`Upon information and belief, DRL was aware of the ʼ010 patent when engaging
`
`in these knowing and purposeful activities and was aware that filing the DRL ANDA constituted
`
`an act of infringement of the ʼ010 patent.
`
`
`
`5
`
`
`
`Case 1:14-cv-00160-RGA Document 1 Filed 02/06/14 Page 6 of 9 PageID #: 6
`
`
`
`28.
`
`Use of DRL’s generic Diprivan® product in accordance with and as directed by
`
`DRL’s proposed labeling for that product would infringe one or more claims of the ʼ010 patent.
`
`29.
`
`Upon information and belief, DRL intends to engage in the manufacture, use,
`
`offer for sale, sale, marketing, distribution, and/or importation of DRL’s generic Diprivan®
`
`product with its proposed labeling immediately and imminently upon approval of the DRL
`
`ANDA.
`
`30.
`
`Upon information and belief, DRL plans and intends to, and will, actively induce
`
`infringement of the ʼ010 patent when the DRL ANDA is approved, and plans and intends to, and
`
`will, do so immediately and imminently upon approval.
`
`31.
`
`Upon information and belief, DRL knows that DRL’s generic Diprivan® product
`
`and the proposed labeling for DRL’s generic Diprivan® product is especially made or adapted for
`
`use in infringing the ʼ010 patent and that DRL’s generic Diprivan® product and the proposed
`
`labeling are not suitable for substantial noninfringing use. Upon information and belief, DRL
`
`plans and intends to, and will, contribute to the infringement of the ʼ010 patent immediately and
`
`imminently upon approval of the DRL ANDA.
`
`32.
`
`The foregoing actions by DRL constitute and/or would constitute infringement of
`
`the ʼ010 patent, active inducement of infringement of the ʼ010 patent, and/or contribution to the
`
`infringement by others of the ʼ010 patent.
`
`33.
`
`Upon information and belief, DRL acted without a reasonable basis for believing
`
`that it would not be liable for infringing the ʼ010 patent, actively inducing infringement of the
`
`ʼ010 patent, and/or contributing to the infringement by others of the ʼ010 patent.
`
`34.
`
`Fresenius will be substantially and irreparably harmed by DRL’s infringing
`
`activities unless the Court enjoins those activities. Fresenius will have no adequate remedy at
`
`
`
`6
`
`
`
`Case 1:14-cv-00160-RGA Document 1 Filed 02/06/14 Page 7 of 9 PageID #: 7
`
`
`
`law if DRL is not enjoined from the commercial manufacture, use, offer to sell, sale in and
`
`importation into the United States of DRL’s generic Diprivan® product.
`
`35.
`
`DRL’s activities render this case an exceptional one, and Fresenius is entitled to
`
`an award of their reasonable attorney fees under 35 U.S.C. § 285.
`
`PRAYER FOR RELIEF
`
`
`
`WHEREFORE, Fresenius respectfully requests the following relief:
`
`a.
`
`A judgment that DRL’s submission of the DRL ANDA No. 205067 infringes one
`
`or more claims of the ʼ010 patent and that the making, using, offering to sell, or selling in the
`
`United States, or importing into the United States of DRL’s generic Diprivan® product prior to
`
`the expiration of the ʼ010 patent will infringe, actively induce infringement, and/or contribute to
`
`the infringement of one or more claims of the patent;
`
`b.
`
`An Order pursuant to 35 U.S.C. § 271(e)(4)(A) providing that the effective date of
`
`any FDA approval of DRL ANDA No. 205067 or any product or compound the use of which
`
`infringes the ʼ010 patent, shall be a date that is not earlier than the expiration of the patent;
`
`c.
`
`An Order permanently enjoining Defendants and all persons acting in concert
`
`with Defendants from commercially manufacturing, using, offering for sale, selling, marketing,
`
`distributing, or importing DRL’s generic Diprivan® product, or any other product or compound
`
`the use of which infringes the ʼ010 patent, or inducing or contributing to the infringement of the
`
`ʼ010 patent patents until after the expiration of the patent;
`
`d.
`
`An Order enjoining Defendants and all persons acting in concert with Defendants
`
`from seeking, obtaining, or maintaining approval of the DRL ANDA No. 205067 before the
`
`expiration of the ʼ010 patent;
`
`
`
`7
`
`
`
`Case 1:14-cv-00160-RGA Document 1 Filed 02/06/14 Page 8 of 9 PageID #: 8
`
`
`
`e.
`
`An award of Plaintiff’s damages or other monetary relief to compensate Plaintiff
`
`if Defendants engage in the commercial manufacture, use, offer to sell, sale or marketing or
`
`distribution in, or importation into the United States of Defendants’ generic Diprivan® product,
`
`or any product or compound the use of which infringes the ʼ010 patent, or the inducement or
`
`contribution of the foregoing, prior to the expiration of the patent in accordance with 35 U.S.C. §
`
`271(e)(4)(C);
`
`f.
`
`A judgment that this is an exceptional case and awarding Plaintiff its attorneys’
`
`fees under 35 U.S.C. § 285;
`
`An award of Plaintiff’s reasonable costs and expenses in this action; and
`
`An award of any further and additional relief to Plaintiff as this Court deems just
`
`g.
`
`h.
`
`and proper.
`
`
`
`8
`
`
`
`Case 1:14-cv-00160-RGA Document 1 Filed 02/06/14 Page 9 of 9 PageID #: 9
`
`
`
`
`
`Dated: February 6, 2014
`
`
`
`
`
`
`
`Of Counsel:
`
`Daryl L. Wiesen
`John Bennett
`Sundar Subramanyam
`Sam Sherry
`Todd Marabella
`Jennifer L. Ford
`GOODWIN PROCTER LLP
`Exchange Place
`53 State Street
`Boston, MA 02109
`(617) 570-1000
`(617) 523-1231 (fax)
`DWiesen@goodwinprocter.com
`
`JBennett@goodwinprocter.com
`SSubramanyam@goodwinprocter.com
`SSherry@goodwinprocter.com
`
`TMarabella@goodwinprocter.com
`
`JFord@goodwinprocter.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`FARNAN LLP
`
`
`/s/ Brian E. Farnan
`Brian Farnan (Bar No. 4089)
`919 North Market Street
`12th Floor
`Wilmington, DE 19801
`Phone: 302-777-0336
`Fax: 302-777-0301
`bfarnan@farnanlaw.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Attorneys for Plaintiff
`Fresenius Kabi USA, LLC
`
`
`
`9
`
`